Ustekinumab-Induced Fatal Acute Heart Failure in a Young Female: A Case Report
References
- Rawal S, Kianian S, Guo W, et al. Alternative uses of ustekinumab for non-indicated dermatological conditions: a systematic review. Arch Dermatol Res. 2021 Jun 22. doi: 10.1007/s00403-021-02262-7. Online ahead of print.
- Beroukhim K, Danesh M, Nguyen C, Koo J, Leon A. A case report of heart failure after therapy with ustekinumab. J Dermatol Dermatol Surg. 2015 Jul;19(2):117–119. doi: 10.1016/j.jdds.2015.03.003
- Ghosh S, Gensler LS, Yang Z, et al. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Saf. 2019 Jun;42(6):751–768. doi: 10.1007/s40264-019-00797-3
- Krulig E, Gordon KB. Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid. 2010 Jul 27;5:11–22. doi: 10.2147/ce.s5994
- Taleb S, Tedgui A, Mallat Z. IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):258–64. doi: 10.1161/ATVBAHA.114.303567
- Poizeau F, Nowak E, Kerbrat S, et al. Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti-Interleukin 12/23p40 Antibody Ustekinumab. JAMA Dermatol. 2020 Nov 1;156(11):1208–1215. doi: 10.1001/jamadermatol.2020.2977
- Simon T, Taleb S, Danchin N, et al. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J. 2013 Feb;34(8):570–7. doi: 10.1093/eurheartj/ehs263
- Savvatis K, Pappritz K, Becher PM, et al. Interleukin-23 deficiency leads to impaired wound healing and adverse prognosis after myocardial infarction. Circ Heart Fail. 2014 Jan;7(1):161–71. doi: 10.1161/CIRCHEARTFAILURE.113.000604
- Langley RG, Lebwohl M, Krueger GG, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172(5):1371–83. doi: 10.1111/bjd.13469
- de Brito M, Yiu ZZN. Cardiovascular Safety of Biologics Targeting Interleukin (IL)-12 and/or IL-23: What Does the Evidence Say? Am J Clin Dermatol. 2021 Sep;22(5):587–601. doi: 10.1007/s40257-021-00612-9
- Ehealthme.com [Internet]. Mountain View, CA: Ehealthme;
c2022. Stelara and Deep venous thrombosis - a phase IV clinical study of FDA data ; 2022 Mar 21 [cited 2022 Jun 10]. Available from:https://www.ehealthme.com/ds/stelara/deep-venous-thrombosis/ - Ikonomidis I, Papadavid E, Makavos G, et al. Lowering Interleukin-12 Activity Improves Myocardial and Vascular Function Compared With Tumor Necrosis Factor-a Antagonism or Cyclosporine in Psoriasis. Circ Cardiovasc Imaging. 2017 Sep 12;10(9):
e006283 . doi: 10.1161/CIRCIMAGING.117.006283 - Huang J, Zhang W, Zhang CL, Wang L. Interleukin-17 aggravates right ventricular remodeling via activating STAT3 under both normoxia and hypoxia. BMC Cardiovasc Disord. 2021 May 21;21(1):249. doi: 10.1186/s12872-021-02069-4
- Chang SL, Hsiao YW, Tsai YN, et al. Interleukin-17 enhances cardiac ventricular remodeling via activating MAPK pathway in ischemic heart failure. J Mol Cell Cardiol. 2018 Sep;122:69–79. doi: 10.1016/j.yjmcc.2018.08.005
DOI: https://doi.org/10.14797/mdcvj.1076 | Journal eISSN: 1947-6108
Language: English
Page range: 54 - 58
Submitted on: Dec 30, 2021
Accepted on: May 10, 2022
Published on: Jul 12, 2022
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
© 2022 Mahmoud Abdelnabi, Saif ElNawaa, Juthipong Benjanuwattra, Mohamed Elmassry, Nandini Nair, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.